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Abstract
Background: Despite efforts to eliminate leprosy as public health problem, delayed diagnosis and disabilities still
occur in many countries. Leprosy diagnosis remains based on clinical manifestations and the number of clinicians
with expertise in leprosy diagnosis is in decline. We have developed a new immunochromatographic test with the
goal of producing a simple and rapid system that can be used, with a minimal amount of training, to provide an
objective and consistent diagnosis of multibacillary leprosy.
Methods: The test immobilizes two antigens that have been recognized as excellent candidates for serologic
diagnosis (the PGL-I mimetic, ND-O, and LID-1), on a nitrocellulose membrane. This allows the detection of specific
IgM and IgG antibodies within 20 minutes of the addition of patient sera. Furthermore, we coupled the NDO-LID®
rapid tests with a new cell phone-based test reader platform (Smart Reader®) to provide objective interpretation
that was both quantifiable and consistent.
Results: Direct comparison of serologic responses indicated that the rapid test detected a greater proportion of
leprosy patients than a lab-based PGL-I ELISA. While positive responses were detected by PGL-I ELISA in 83.3% of
multibacillary patients and 15.4% of paucibacillary patients, these numbers were increased to 87% and 21.2%,
respectively, when a combination of the NDO-LID® test and Smart Reader® was used. Among multibacillary leprosy
the sensitivity of NDO-LID® test assessed by Smart Reader® was 87% (95% CI, 79.2-92.7%) and the specificity was
96.1% (95% CI, 91.7- 98.6%). The positive predictive value and the negative predictive value of NDO-LID® tests were
94% (95% CI, 87.4-97.8%) and 91.4% (95% CI, 85.9-95.2%), respectively.
Conclusion: The widespread provision of rapid diagnostic tests to facilitate the diagnosis or prognosis of
multibacillary leprosy could impact on leprosy control programs by aiding early detection, directing appropriate
treatment and potentially interrupting Mycobacterium leprae transmission.
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Background
Leprosy is a dermato-neurological disease that remains
an important public health problem in many countries.
Patients present with a spectrum of immunological, histo-
logical and clinical manifestations that depend on the host
immune response to Mycobacterium leprae [1,2]. Clinical
manifestations range from the polar lepromatous (LL)
forms with high bacterial index (BI), weak M. leprae
specific cell mediated immunity (CMI) and high anti-
body titers, to tuberculoid (TT) forms that have low BI,
strong CMI and low antibody production. Early diagno-
sis and treatment are recognized as key elements in the
prevention of long-term sequelae associated with lep-
rosy, such as significant impairment of nerve function
and deformities, and disabilities are found at greater fre-
quency and severity in patients for whom diagnosis was
significantly delayed [3]. In addition, multibacillary (MB)
patients with high bacterial burdens are believed to be the
primary transmitters of leprosy’s etiologic agent, M. leprae,
so recognizing and treating infection in these individuals
is likely to reduce transmission. Leprosy diagnosis is still,
however, based on the recognition of clinical manifes-
tations and reduction in the number of clinicians with
expertise in its diagnosis, even in endemic countries, is
likely contributing to delayed diagnosis or misdiagnosis [4,5].
There is an expectation that specific and sensitive
tests will aid leprosy control programs to further the
push toward eliminating this disease. With a goal of devel-
oping such tests, antibody responses of leprosy patients to
M. leprae proteins and lipids have been extensively investi-
gated, with M. leprae-specific phenolic glycolipid I (PGL-I)
antigen representing the most thoroughly investigated
to date. Several studies have demonstrated that the
anti-PGL-I response is strong among MB patients and
reflects the bacillary load, and lateral flow tests have
previously been developed to detect the IgM response
to PGL-I (ML Flow) and IgM, IgG and IgA antibodies
(ML ICA) [6]. Not surprisingly given the limited anti-
body response of paucibacillary (PB) patients, these
tests have limited sensitivity for the detection of PB pa-
tients with low BI [7,8]. No objective test for the diagnosis
or prognosis of leprosy is, however, currently commer-
cially available.
Our group has previously described novel antigenic
proteins that clearly differentiate MB patients from healthy
and M. tuberculosis-infected controls in endemic areas,
therefore appearing suitable for the development of
serologic tests for leprosy [9-11]. LID-1, a fusion of the
ML0405 and ML2331 proteins, has proven to be strongly
reactive with MB patients sera in many geographic loca-
tions [10,12-14]. Previous data have suggested that the
addition of LID-1 protein to PGL-I could improve sensi-
tivity in a diagnostic test, since some patients lacking anti-
PGL-I antibodies have antibodies that recognize LID-1,
and vice versa [12]. Furthermore, the progression of anti-
body responses against either PGL-I and LID-1 has been
demonstrated to predict the onset of MB leprosy in ex-
perimental and clinical surveillance settings [10,14-16].
With a goal of producing a simple and rapid test that
can be used with a minimal amount of training to pro-
vide an objective and consistent diagnosis of MB leprosy,
we developed and evaluated a new rapid test for MB lep-
rosy that incorporates both the LID-1 and PGL-I anti-
gens. These antigens were immobilized on nitrocellulose
membranes that permit transfer and detection of specific
antibodies in patient’s sera. When coupled with a new cell
phone-based test reader platform (Smart Reader® applica-
tion), these tests can provide quantifiable and consistent
data to assist in the diagnosis of MB leprosy. The devel-
opment and widespread provision of rapid tests for MB
leprosy diagnosis, prognosis or classification could have
an important impact on leprosy control programs by
facilitating/promoting early MB diagnosis, appropriate
treatment and interruption of M. leprae transmission.
Methods
Study groups
Between 2006 and 2012, 441 participants were recruited
in Goiânia city, Goiás State, Brazil, an endemic area for
leprosy, under the approval of the local review board
(Comitê de Ética em Pesquisa Humana e Animal/Hospital
das Clínicas/Universidade Federal de Goiás) and National
Ethics Commission (Comissão Nacional de Ética Pesquisa/
CONEP/Brazil, protocols#4862/#12962). All participants
(or legal guardians of patients under 18 years) signed an
informed consent before blood collection. The test
evaluations included five study groups: 1. Newly diag-
nosed, untreated MB leprosy patients (n = 108); 2. Newly
diagnosed, untreated PB leprosy patients (n = 104); 3.
Household contacts of MB and PB leprosy patients (HHC,
n = 75); 4. Pulmonary tuberculosis patients with positive
bacilloscopy, seronegative for HIV-1/2 and under specific
treatment for at least three months (TB, n = 53); 5.
Healthy endemic controls; defined as individuals with-
out previous history of leprosy or TB diagnosis who
were not intra-domicilary contacts of leprosy patients
(EC, n = 101). Participants from both sexes and from
all age ranges were included. Leprosy patients were
recruited at the main regional public health outpatient
clinic (Centro de Referência em Diagnóstico e Terapêutica,
Goiânia city, Goiás State) and classified taking into
consideration clinical, bacilloscopic and histopathologic
data [1]. PB leprosy included TT and borderline-tuberculoid
(BT) patients and MB group included patients in the
borderline-borderline (BB), borderline-lepromatous (BL)
and LL categories.
The Table 1 describes the main characteristics among
the study groups. Among MB leprosy patients 36.1%
Cardoso et al. BMC Infectious Diseases 2013, 13:497 Page 2 of 10
http://www.biomedcentral.com/1471-2334/13/497
were LL (39/108), 39.8% were BL (43/108) and 24.1%
were BB (26/108), with a median bacterial index (BI) of
1.0. The PB leprosy group was composed by 41.4% TT
patients (43/104) and 58.7% BT patients (61/104). The
HHC group included both contacts of MB leprosy pa-
tients (80%; 60/75) and contacts of PB leprosy patients
(20%; 15/75). The control groups included: TB patients
(n = 53) and EC (n = 101).
Enzyme linked immunosorbent assay (ELISA)
ELISA for the detection of IgM antibodies to PGL-I was
performed as previously described [17,18]. In brief, the
natural trisaccharide-phenyl analog of PGL-I conjugated
to bovine serum albumin (NT-P-BSA) was used as anti-
gen and the BSA alone was used as control (Sigma-Aldrich,
St. Louis, USA). Serum samples were diluted 1:300 (PBS-
BSA with 10% normal goat serum/NGS, Sigma-Aldrich,
St. Louis, USA) and tested in duplicate. The reaction
was developed by the addition of peroxidase-conjugated
anti-human IgM (Cappel/Organon Teknika, Turnhout,
Belgium) and 3,3′,5,5′-tetramethylbenzidine liquid as
substrate system (TMB, Sigma-Aldrich, St. Louis, USA).
To control intra- and inter-test variation, a standard
reference serum was included in triplicate in each
plate. The reaction was quenched by the addition of
2.5 N H2SO4 (Sigma-Aldrich, St. Louis, USA) when the
optical density (OD) at 450 nm from the standard ref-
erence serum reached a value of 0.7. The cut-off value
for positive results was OD ≥ 0.250. Total assay time was
3 hours.
NDO-LID® rapid test
NDO-LID® rapid test (Orange Life®, Rio de Janeiro, Brazil)
was developed by impregnating nitrocellulose membranes
with ND-O-LID-1, a conjugation of the ND-O (a synthetic
mimetic of PGL-I disaccharide) and the LID-1 protein
[10,19,20]. Panels of well characterized sera from leprosy
patients and controls were used to evaluate several proto-
types in order to define the final test configuration. The
NDO-LID® test is provided as a ready-to-use kit and was
performed by adding undiluted serum (10 μl) and running
buffer (100 μl) into the sample well, causing the migration
of the sample and colloidal gold beads loaded with anti-
IgG and anti-IgM through the membrane and across a de-
tection window. Interactions with the test and/or control
lines are revealed as a red color. Readings were performed
after 20 minutes.
Validation of the results required the visualization of a
clear control line in the detection window. A positive re-
sult was defined by the staining of both the control line
and the test line (visual reading scores: 1+/1.5+/2+);
faint or no test line staining was considered as a negative
result (Figure 1A and B). Visual readings were performed
by three independent readers. In addition, readings were
performed using a new Smart Reader® platform (Orange
Life®) (Figure 1C) similar to that previously tested with
malaria, TB and HIV rapid tests [21,22]. The calculation
of Smart Reader® cut-off values was based on the Receiver
Operating Curve (ROC), taking into account the visual
results of the tests obtained with MB leprosy patient
samples and control samples (TB and EC). Assuming a
sensitivity of 87%, as determined by visual readings, the
Smart Reader® cut-off was calculated as 9.99 (Figure 2).
For data analysis the cut-off for positive results by Smart
Reader® was therefore considered as 10.0. Assuming this
cut-off, the sensitivity of the test for MB leprosy was
87% (95% confidence interval (CI): 79.2 to 92.7%) and
the specificity was 96.1% (CI 95%: 91.7 to 98.6%), with
an area under the curve (AUC) of 0.96 (standard devi-
ation, sd 0.01; p < 0.0001). To validate readings performed
Table 1 Main characteristics among the study groups recruited in Brazil
MB PB HHC TB EC
Sex (Female/Male) 43/65 48/56 40/35 18/53 78/23
Age (median range, years) 48 (20–100) 42.5 (14–77) 36.5 (18–60) 40 (17–67) 25 (19–66)
R & J classification
LL 39 (36.1%) - - - -
BL 43 (39.8%) - - - -
BB 26 (24.1%) - - - -
BT - 61 (41.4%) - - -
TT - 43 (58.7%) - - -
Total/group 108 104 75 53 101
TOTAL = 441
BB borderline-borderline, BL borderline lepromatous, BT borderline- tuberculoid, EC healthy endemic controls, HHC household contacts, LL polar lepromatous,
MB multibacillary leprosy, PB paucibacillary leprosy, R & J Ridley & Jopling, TB tuberculosis patients, TT polar tuberculoid.
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by Smart Reader® for NDO-LID® test, the positive predict-
ive value (PPV) and the negative predictive value (NPV)
were calculated as 94% and 91.4%, respectively.
Statistical analysis
Frequencies, median, mean of OD values and graphics
were obtained (GraphPad Prism version 5). Statistical
significance was assessed using Kruskal-Wallis one-way
analysis of variance for comparison of multiple groups
and by Mann–Whitney U test for comparison between
two groups. Results were considered statistically signifi-
cant when p values < 0.05 were obtained.
The concordance between results of the ELISA and
NDO-LID® tests was determined by agreement and kappa
values (κ) with 95% CI and sd value were calculated
(Statistical Package for the Social Sciences, SPSS version
13.0). The following interpretation of agreement was used
for the kappa values: low (0–0.5), moderate (0.51-0.75) and
excellent (0.76-1.0) following established guidelines [23].
The accuracy of the NDO-LID® tests was evaluated by
ROC (GraphPad Prism version 5) considering the AUC,
in which a test that does not discriminate healthy individuals
from patients, gives a value of AUC of 0.5 (null hypothesis).
In our case the test discriminates MB leprosy from the
other groups. A value above 0.7 is considered a satisfac-
tory performance [24]. Moreover, the sensitivity, specifi-
city and the PPV and NPV values were determined with
95% CI (GraphPad Prism version 5).
Results
Detection of MB patients by serologic tests
The anti-PGL-I ELISA positive rate among the MB lep-
rosy patients tested was determined to be 83.3% (90/108;
median OD = 0.766, range 0.285 to 2.755). As expected,
seropositivity varied across the different MB leprosy
categories: 92.3% for LL patients (36/39; median OD =
0.756, range 0.333 to 2.688), 69.8% for BL patients (30/43;
median OD= 0.754, range 0.313 to 2.566) and 92.3% for
BB patients (24/26; median OD = 0.772, range 0.285 to
2.755) (Figure 3A).
Among these same MB leprosy patients, the seropositive
rate in NDO-LID® test was found to be slightly higher at
87% (94/108), with similar results obtained by both visual
reading and the Smart Reader® platform (Figures 3B
and C). These results demonstrate concordance at both
performance and signal intensity of laboratory-based
assays with the rapid test/Smart Reader® application. A
decrease in the score of visual reading was observed
across the spectrum of the disease from the MB (LL, BL
and BB) to PB (TT, BT) pole when using the NDO-LID®
tests (Figure 3B). Positive rates ranged from 97.4% for LL
(38/39; median = 58, range 11 to 92.5), 83.7% among BL
(36/43; median = 21.9, range 15.1 to 90.1) and 76.9%
among BB leprosy (20/26; median = 44.9, range 10 to
44.9). Thus, similar declines in signal intensity across
the clinical spectrum were measured by the Smart
Reader® application, although a far greater range of sig-
nal intensity was captured by the electronic reader
(Figure 3C). Although not statistically significant, the
NDO-LID® rapid test actually slightly outperformed
laboratory-based anti-PGL-I ELISA, suggesting an added
benefit by including the LID-1 protein and indicating utility
for the clear and simple detection of MB leprosy patients.
B
A C
Figure 1 NDO-LID® rapid test. A.: A positive result was defined by the staining of both the control line and the test line (visual reading scores:
1+/1.5+/2+; Smart Reader® readings >10). B.: A negative result was defined when a clear control line, but only faint or absent test line, staining
was observed. C.: Readings and objective scoring were achieved using a new Smart Reader® platform.
Figure 2 Receiver Operating Curve (ROC) for NDO-LID® test for
leprosy. The insert indicates 87% of sensitivity.
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Enhanced detection of PB leprosy by NDO-LID® test
As expected, when samples from PB leprosy patients
were evaluated, the anti-PGL-I ELISA was found to be
positive in only a minor subset, and with a reduced sig-
nal intensity compared to MB patients. An overall rate
of 15.4% positive responders were found for PB patients
(16/104; median OD = 0.454, range 0.300 to 1.126),
ranging from 14.8% among BT patients (9/61; median
OD = 0.359, range 0.346 to 1.126) to 16.3% for TT pa-
tients (7/43; median OD = 0.408, range 0.300 to 0.581)
(Figure 3A).
As with the evaluations in MB patients, an increased
number of PB patients was detected by the NDO-LID®
test. The NDO-LID® rapid test was visually positive
for 20.2% of PB leprosy patients (21/104): 26.2% for
BT patients (16/61) and 11.6% for TT patients (5/43)
(Figure 3B). NDO-LID® results assessed by Smart Reader®
platform demonstrated a 21.2% positivity rate for PB
leprosy patients (22/104): 26.2% among BT patients
(16/61; median = 15.85, range 10.4 to 45.5) and 14%
among TT patients (6/43; median = 12.6, range 10.2 to
19.5) (Figure 3C). Although these data indicate limited
utility of the serological assays for detection of PB cases,
they do indicate that some PB patients can actually be
detected by this simple rapid test. This was particularly
true for BT patients, where the rapid test almost doubled
the detection rate over PGL-I ELISA.
Seroreactivity among HHC and control groups
HHC of untreated MB patients represent an important
study group as they are believed to be exposed to
M. leprae at a higher frequency than the general popula-
tion and seropositive contacts are considered to be at
higher risk of progressing towards MB disease. In this
study we tested HHC of both PB and MB patients.
Overall, anti-PGL-I ELISA positivity among HHC was
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Figure 3 PGL-I ELISA and NDO-LID® tests assessed among multibacillary (MB) and paucibacillary (PB) leprosy groups. The number above
each data set is the percentage of positive results and the number below each data set represents the total number of participants of each
group. A.: IgM PGL-I ELISA test: each point represents the mean value of optical density (OD) of individual serum samples. The median OD value
of each group is represented by the horizontal line. The traced horizontal line is the cut-off (OD≥ 0.250). * = p < 0.05 (LL versus BT and TT; BL versus BT
and TT; BB versus BT and TT). B.: Visual reading of NDO-LID® test scored * = p < 0.05. C.: NDO-LID® test assessed by Smart Reader® platform: each point
represents the Smart Reader® result of an individual serum sample. The horizontal line represents the median of the Smart Reader® reading for each
group and the traced horizontal line is the cut-off (≥ 10). * = p < 0.05 (LL versus BT and TT; BL versus BT and TT; BB versus BT and TT).
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low (2.7%, 2/75): one contact from MB and another
contact from PB leprosy patient (OD = 0.308 and 0.289,
respectively) (Figure 4A).
For the NDO-LID® test an identical rate of seroposi-
tivity was detected in HHC by visual reading and by
Smart Reader® (5.3%; 4/75); detecting 2 additional indi-
viduals along with both that were anti-PGL-I positive by
ELISA (one of them HHC of MB patient and the other
HHC of PB patient) (Figures 4B and C). For the two MB
HHC seropositive, the Smart Reader® readings were 16.8
and 21.8 and for the two PB HHC seropositive, the
Smart Reader® readings were 11.4 and 14.4, respectively.
Among TB patients the overall anti-PGL-I ELISA
positivity was 3.8% (2/53; OD = 0.301 and 0.302) and no
responses were observed among EC (Figure 4A). For TB
patients tested by NDO-LID® the same positive rate was
obtained by visual reading and by Smart Reader® read-
ings (5.7%, 3/53). For EC 4% (4/101) were positive by
visual reading, while 3% were positive using the Smart
Reader® (3/101, p > 0.05) (Figures 4B and C). Together,
these data indicate that, despite possible cross-reactivity
with other mycobacteria circulating in the test popula-
tions, the rapid test is highly specific for leprosy.
NDO-LID® rapid test enhances patient detection over
anti-PGL-I ELISA
For the NDO-LID® test adopting the Smart Reader®
cut-off ≥ 10, a high degree of agreement (99.1%; 437/441)
was observed between the visual reading and the Smart
Reader® (kappa value = 0.98; sd = 0.011) (Table 2). The
four discordant cases were a single TT patient (negative
by visual reading and Smart Reader® positive = 10.2), a
single EC (positive by visual reading and Smart Reader®
negative) and two TB patients (one positive by visual
reading, negative in Smart Reader® and one negative by
visual reading and Smart Reader® positive = 10.8).
In 90.9% (401/441) of the samples anti-PGL-I ELISA
and NDO-LID® results were concordant (either positive
or negative; kappa value = 0.8; sd = 0.034) (Table 3). Among
these, 98 were positive in both tests (86 MB leprosy; 10 PB;
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Figure 4 PGL-I ELISA and NDO-LID® tests assessed among household contacts (HHC), tuberculosis (TB) patients and healthy endemic
control (EC) groups. The number above each data set is the percentage of positive results and the number below each data set represents the
total number of participants of each group. A.: IgM PGL-I ELISA test: each point represents the mean value of optical density (OD) of individual
serum samples. The median OD value of each group is represented by the horizontal line. The traced horizontal line is the cut-off (OD ≥ 0.250).
* = p < 0.05 (HHC-MB versus TB and EC; HHC-PB versus EC). B.: Visual reading of NDO-LID® test scored. C.: NDO-LID® test assessed by Smart Reader®
platform: each point represents the Smart Reader® result of an individual serum sample. The horizontal line represents the median of the
Smart Reader® reading for each group and the traced horizontal line is the cut-off (≥ 10).
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2 HHC) and 303 samples were negative in both tests. The
discordant rate observed between the NDO-LID® and anti-
PGL-I ELISA test was 9.1% (40/441). A total of 28 NDO-
LID® positive results were revealed among 331 anti-PGL-I
ELISA negative samples: 8 from MB leprosy patients, 11
from PB leprosy, 2 from HHC, 3 from TB patients, 4
from EC. Conversely, only 12 negative NDO-LID® tests
were found among anti-PGL-I positive samples: 4 from
MB leprosy (median anti-PGL-I OD = 0.539, range 0.315 -
0.757), 6 from PB leprosy patients (median OD= 0.575,
range 0.300 - 0.409) and 2 from TB patients (OD = 0.301
and 0.302).
Discussion
Although leprosy remains an important public health
problem in many countries, including Brazil, diagnosis is
still based on the recognition of clinical manifestations
by highly skilled clinicians [25]. A major concern in the
widespread control efforts for leprosy is, however, that
even in endemic regions the number of such clinicians
that can actually recognize early signs or provide a confident
differential diagnosis from other skin diseases is limited
and in decline [4,26]. Tests that could be conducted on
individuals with even a minimal suspicion of leprosy by
general health workers, in conjunction with clinical exam
by physicians, could facilitate referrals or initiate increased
levels of monitoring.
The application of a rapid test for leprosy needs to
take into account both the spectral nature of the disease
and the immunological dichotomy in which at one pole
PB patients develop weak (or absent) antibody responses
while at the opposite pole MB patients develop a robust
humoral immune response. The PGL-I and LID-1 anti-
gens have been among the most reactive antigens tested
in different populations, including multiple sites in Brazil,
the Philippines, Japan, Nepal, Venezuela, Bangladesh, and
India, suggesting utility in a global context [10,12,13]. As
expected, the majority of MB leprosy patients were identi-
fied by serological assays, yielding higher responses than
PB patients. Some studies have reported a moderate fre-
quency of anti-PGL-I antibodies and anti-IgG antibodies
to recombinant M. leprae proteins in PB leprosy patients
(range 15 to 40%) [8,10,11]. An important limitation that
must therefore be recognized for any serological test for
leprosy is that their ability to detect PB patients may be
limited. Given the results of anti-PGL-I ELISA, the sero-
positivity among PB leprosy patients by NDO-LID® rapid
test in this study can be considered higher than expected
(20.2%). The intra-domiciliary contacts of leprosy patients,
especially MB patients, likely have a markedly increased
rate of infection and absolutely have an increased risk of
developing MB leprosy compared to the general popula-
tion; among anti-PGL-I positive contacts this elevated risk
is even higher [27,28]. We observed low response rates
among contacts from both MB and PB leprosy patient
groups, suggesting that positive tests may be indicative of
symptomatic leprosy or asymptomatic M. leprae infection
and not simply exposure. It should be noted that, even in
a groups of 75 contacts and over 100 healthy controls as
tested here, only few actual cases are predicted to emerge.
Laboratory-based studies have already been used to alert
surveillance teams to individuals that have developed
clinical symptoms subsequent to strong results in LID-1
ELISA, at levels that are readily detected in the rapid
test [14,16]. Expanded evaluations, either through bridging
studies of archived sera or preferably through ‘live’ testing
as a component of sustained monitoring campaigns,
are needed to better indicate the potential benefits of
incorporating such a test by leprosy control programs
in endemic countries. The rapidity and ease-of-use of
the test also suggests that expanded screening within
patient populations and their contacts including indi-
viduals younger than 15 years could be readily achievable
and would provide important information for leprosy
control programs.
For operational purposes a simplified leprosy classifi-
cation system based on the number of skin lesions de-
fines that PB leprosy presents with up to five lesions and
usually include TT and BT forms whereas MB leprosy
presents with more than five skin lesions and usually
comprise LL, BL and BB forms [29]. However, the ac-
curacy of this classification criterion is limited and may
lead to misclassification and inadequate treatment [30,31].
Differentiation to the general classifications orients spe-
cific multidrug therapy (MDT) which consists of either
six doses of rifampim and dapsone for PB leprosy or
twelve doses of rifampim, dapsone and clofazimine for
MB patients. Several studies have identified that anti-
PGL-I responses and the ML Flow rapid test can help in
the classification of MB and PB leprosy patients to ori-
ent the choice of treatment [6,8,32,33]. The rapid test
Table 2 NDO-LID® test results: comparison between visual
reading and Smart Reader®
NDO-LID® test Visual reading
Positive Negative Total
Smart Reader® platform Positive 124 3 127
Negative 1 313 314
Total 125 316 441
Table 3 NDO-LID® and IgM anti-PGL-I ELISA results
NDO-LID® test
Positive Negative Total
PGL-I ELISA Positive 98 12 110
Negative 28 303 331
Total 128 313 441
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that we have developed retains the ability to aid MB and
PB leprosy classification, although the ability to ‘diagnose’
PB leprosy remains limited. This is not surprising given
the generally low anti-M. leprae antibody responses of
PB patients. It has been previously reported that serum
antibody responses to PGL-I and to LID-1 antigens decline
upon MDT [15,34]. Importantly, given the enhanced fidel-
ity of rapid test interpretation when incorporated with the
Smart Reader®, monitoring of patients on treatment could
potentially reveal complications such as relapses (or reinfec-
tion), providing improved patient care and management.
Typically, lateral flow-based rapid test have been scored
subjectively on a grading system after visual inspection.
Even with comparative examples, it is difficult to achieve
consistency in these readings unless the reader(s) has gar-
nered a large amount of experience. Additionaly, results
from any diagnostic test would ideally be blinded from the
clinical evaluation but in most settings, such as rural set-
tings with limited resources and personnel or busy urban
clinics, this is difficult to achieve. Considering the possibil-
ity of incorrect or bias in human reading of rapid tests
in field conditions, an important innovation presented
in this study is the use of a digital and automated rapid
test Smart Reader® application. At the sole additional
expense of a standard cell phone, this provides a means
to generate controlled and consistent results across di-
verse endemic settings. As an extra layer of quality con-
trol and patient care, this compact pocket-size digital
reader permits the transmission of digital data and other
related information (e.g., demographic data) to a cloud,
allowing the information to be downloaded for record
keeping and/or be transferred to off-site experts for a
rapid second opinion. This new technological strategy
also allows real time spatio-temporal analysis of the disease
prevalence and incidence in the region under evaluation.
For any serological test, both sensitivity and specificity
represent the main parameters which were evaluated in
this study by the inclusion of well characterized newly
diagnosed, untreated leprosy patients (clinical, histo-
pathological and microbiological features) and controls
from an endemic area (EC and patients with TB). Among
MB leprosy the sensitivity of NDO-LID® test assessed by
Smart Reader® was 87% (95% CI, 79.2-92.7%) and the spe-
cificity was 96.1% (95% CI, 91.7- 98.6%). The PPV and the
NPV of NDO-LID® tests were 94% (95% CI, 87.4-97.8%)
and 91.4% (95% CI, 85.9-95.2%), respectively. Potential
cross-reactivity is an important issue to be considered
in the development of a new serologic test, particularly
for countries with a high incidence of TB, high BCG
vaccination coverage and high levels of exposure to en-
vironmental mycobacteria [35,36]. Using NDO-LID® test
low positivity among healthy EC was observed. This is
an important data since for most individuals from an
endemic country, such as Brazil, there is a high chance
of exposure to M. leprae throughout life especially in
the highly endemic Northeast, North and Central Western
regions, the latter representing the area where partici-
pants were recruited. Moreover the geographical region
where participants were recruited is characterized by a
very high BCG vaccination coverage (close to 100%).
The low NDO-LID® positivity among TB and EC indi-
cates that previous BCG vaccination, at least within the
age range of participants is not associated with cross
reactivity in the new rapid test [6,37]. The low sero-
positivity among TB patients observed with NDO-LID®
test indicates that cross-reaction between M. tuberculosis
antigens is not a significant concern. For the 3 (out of 53)
TB patients with positive NDO-LID® test, subclinical in-
fection or exposure to M. leprae cannot not be excluded.
In general, the low positivity among control groups fur-
ther supports the use of NDO-LID® test in an endemic
country as Brazil.
Conclusions
The new NDO-LID® rapid test presented in this study
represents an important development in leprosy control,
capable of providing a practical means to assist in the
rapid, consistent and quantitative detection of MB leprosy.
Considering the need for a rapid test in leprosy endemic
countries, broader validation studies are being developed
to evaluate performance under field conditions, including
the direct use of finger prick blood samples to demon-
strate its utility as a true point of care test. The NDO-LID®
rapid test could ultimately aid leprosy control programs
by allowing greater numbers of individuals to be simply
tested at a greater frequency, and could be instrumental in
the identification and prompt treatment of MB patients.
Together, such applications of the test could help reach
the WHO recommendation of early diagnosis to interrupt
the transmission of M. leprae and further reduce leprosy
case numbers.
Abbreviations
AUC: Area under the curve; BI: Bacterial index; BB: Borderline-borderline;
BL: Borderline-lepromatous; BT: Borderline-tuberculoid; BSA: Bovine serum
albumin; CMI: Cell mediated immunity; CI: Confidence interval; ELISA: Enzyme
linked immunosorbent assay; EC: Healthy endemic controls; HHC: Household
contacts; κ: Kappa values; LL: Lepromatous; M. leprae: Mycobacterium leprae;
M. tuberculosis: Mycobacterium tuberculosis; MB: Multibacillary; MDT: Multidrug
therapy; NPV: Negative predictive value; NGS: Normal goat serum;
OD: Optical density; PB: Paucibacillary; PGL-I: Phenolic glycolipid I;
PPV: Positive predictive value; ROC: Receiver operating curve; sd: Standard
deviation; SPSS: Statistical package for the social sciences; ND-O: Synthetic
mimetic of PGL-I disaccharide; TT: Tuberculoid; TB: Tuberculosis;
TMB: 3,3′,5,5′-tetramethylbenzidine.
Competing interests
The authors declare that they have no competing interests. Marco Collovati
is the owner of Orange Life® (Rio de Janeiro/Brazil), the company producing
and marketing the NDO-LID® rapid test and Ronaldo Ferreira Dias, Orange
Life® employee.
Cardoso et al. BMC Infectious Diseases 2013, 13:497 Page 8 of 10
http://www.biomedcentral.com/1471-2334/13/497
Authors’ contributions
LPVC participated in the study designs, carried out the immunoassays,
performed the statistical analysis and drafted the manuscript. RFD participated
in the study design and carried out the immunoassays. AAF, EMH and RMO
participated in the field work and carried out the immunoassays. MC
participated in the study design. SGR participated in the study design and
reviewed the manuscript. MSD conceived, participated in the study design and
contributed to write the manuscript. MMAS conceived, designed the study,
coordinated the field work, analyzed the data and contributed to write the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by American Leprosy Missions, Renaissance Health
Service Corporation and PRONEX/FAPEG/CNPq-07/2009. Dr. Mariane M. A. Stefani
is a recipient of a fellowship from CNPq (grant # 304869/2008-2) and Dr. Ludimila
Cardoso was supported by a fellowship from CAPES (grant#02479/09-5). We thank
Dr. Fujiwara (Institute for Natural Science, Nara University, Nara, Japan) for kindly
providing the NTP-BSA antigen.
Author details
1Tropical Pathology and Public Health Institute, Federal University of Goiás,
235th Street, Setor Universitário, 74605-050 Goiânia-Goiás, Brazil. 2Orange Life,
Rio de Janeiro, Brazil. 3Infectious Disease Research Institute, Seattle, USA.
Received: 28 May 2013 Accepted: 17 October 2013
Published: 23 October 2013
References
1. Ridley DS, Jopling WH: Classification of leprosy according to immunity.
A five-group system. Int J Lepr Other Mycobact Dis 1966, 34:255–273.
2. Modlin RL: The innate immune response in leprosy. Curr Opin Immunol
2010, 22(1):48–54.
3. Scollard DM: The biology of nerve injury in leprosy. Lepr Rev 2008,
79(3):242–253.
4. Siddiqui MR, Velidi NR, Pati S, Rath N, Kanungo AK, Bhanjadeo AK, Rao BB,
Ojha BM, Krishna Moorthy K, Soutar D, Porter JD, Ranganadha Rao PV:
Integration of leprosy elimination into primary health care in orissa,
India. PLoS One 2009, 18(12):e8351.
5. Correa RDA, Aquino DM, Caldas AJ, Amaral DK, França FS, Mesquita ER:
Epidemiological, clinical, and operational aspects of leprosy patients
assisted at a referral service in the state of Maranhão, Brazil. Rev Soc Bras
Med Trop 2012, 45(1):89–94.
6. Stefani MM, Grassi AB, Sampaio LH, Sousa AL, Costa MB, Scheelbeek P,
Neupane KD, Hagge DA, Macdonald M, Cho SN, Oskam L, Bührer-Sékula S:
Comparison of two rapid tests for anti-phenolic glycolipid-I serology in
Brazil and Nepal. Mem Inst Oswaldo Cruz 2012, 107(Suppl):124–131.
7. Klatser PR, Cho SN, Brennan PJ: The contribution of serological tests to
leprosy control. Int J Lepr Other Mycobact Dis 1996, 64(Suppl):S63–S67.
8. Bührer-Sékula S, Smits HL, Gussenhoven GC, van Leeuwen J, Amador S,
Fujiwara T, Klatser PR, Oskam L: Simple and fast lateral flow test for
classification of leprosy patients and identification of contacts with high
risk of developing leprosy. J Clin Microbiol 2003, 41(5):1991–1995.
9. Reece ST, Ireton G, Mohamath R, Guderian J, Goto W, Gelber R, Groathouse N,
Spencer J, Brennan P, Reed SG: ML0405 and ML2331 are antigens of
Mycobacterium leprae with potential for diagnosis of leprosy. Clin Vaccine
Immunol 2006, 13(3):333–340.
10. Duthie MS, Goto W, Ireton GC, Reece ST, Cardoso LP, Martelli CM, Stefani MM,
Nakatani M, de Jesus RC, Netto EM, Balagon MV, Tan E, Gelber RH, Maeda Y,
Makino M, Hoft D, Reed SG: Use of protein antigens for early serological
diagnosis of leprosy. Clin Vaccine Immunol 2007, 14:1400–1408.
11. Sampaio LH, Stefani MM, Oliveira RM, Sousa AL, Ireton GC, Reed SG, Duthie MS:
Immunologically reactive M. leprae antigens with relevance to diagnosis
and vaccine development. BMC Infect Dis 2011, 11:26–37.
12. Hungria EM, Oliveira RM, Souza AL, Costa MB, Souza VN, Silva EA, Moreno FR,
Nogueira ME, Costa MR, Silva SM, Bührer-Sékula S, Reed SG, Duthie MS,
Stefani MM: Seroreactivity to new Mycobacterium leprae protein
antigens in different leprosy-endemic regions in Brazil. Mem Inst
Oswaldo Cruz 2012, 107(Suppl):S104–S111.
13. Rada E, Duthie MS, Reed SG, Aranzazu N, Convit J: Serologic follow-up of
IgG responses against recombinant mycobacterial proteins ML0405,
ML2331 and LID-1 in a leprosy hyperendemic area in Venezuela.
Mem Inst Oswaldo Cruz 2012, 107(Suppl):90–94.
14. Qiong-Hua P, Zhong-Yi Z, Jun Y, Yan W, Lian-Chao Y, Huan-Ying L, Reed SG,
Duthie MS: Early Revelation of Leprosy in China by Sequential Antibody
Analyses with LID-1 and PGL-I. J Trop Med 2013, 2013:352689.
15. Duthie MS, Truman RW, Goto W, O’Donnell J, Hay MN, Spencer JS, Carter D,
Reed SG: Insight toward early diagnosis of leprosy through analysis of
the developing antibody responses of Mycobacterium leprae-infected
armadillos. Clin Vaccine Immunol 2011, 18(2):254–259.
16. Spencer JS, Duthie MS, Geluk A, Balagon MF, Kim HJ, Wheat WH, Chatterjee D,
Jackson M, Li W, Kurihara JN, Maghanoy A, Mallari I, Saunderson P, Brennan PJ,
Dockrell HM: Identification of serological biomarkers of infection, disease
progression and treatment efficacy for leprosy. Mem Inst Oswaldo Cruz 2012,
107(Suppl):79–89.
17. Brett SJ, Payne SN, Gigg J, Burgess P, Gigg R: Use of synthetic
glycoconjugates containing the Mycobacterium leprae specific and
immunodominant epitope of phenolic glycolipid I in the serology of
leprosy. Clin Exp Immunol 1986, 64(3):476–483.
18. Bührer-Sékula S, Sarno EN, Oskam L, Koop S, Wichers I, Nery JA, Vieira LM,
de Matos HJ, Faber WR, Klatser PR: Use of ML dipstick as a tool to classify
leprosy patients. Int J Lepr Other Mycobact Dis 2000, 68:456–463.
19. Cho SN, Fujiwara T, Hunter SW, Rea TH, Gelber RH, Brennan PJ: Use of an
artificial antigen containing the 3,6-di-O-methyl-beta-D-glucopyranosyl
epitope for the serodiagnosis of leprosy. J Infect Dis 1984, 150(3):311–322.
20. Fujiwara T, Hunter SW, Cho SN, Aspinall GO, Brennan PJ: Chemical
synthesis and serology of disaccharides and trisaccharides of phenolic
glycolipid antigens from the leprosy bacillus and preparation of a
disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun
1984, 43(1):245–252.
21. Lee DS, Jeon BG, Ihm C, Park JK, Jung MY: A simple and smart
telemedicine device for developing regions: a pocket-sized colorimetric
reader. Lab Chip 2011, 7:120–126.
22. Mudanyali O, Dimitrov S, Sikora U, Padmanabhan S, Navruz I, Ozcan A:
Integrated rapid-diagnostic-test reader platform on a cellphone. Lab Chip
2012, 7(15):2678–2686.
23. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S:
Reproducibility of histomorphologic diagnoses with special reference to
the Kappa statistic. APMIS 1989, 97:689–698.
24. Beck JR, Shultz EK: The use of relative operating characteristic (ROC)
curves in test performance evaluation. Arch Pathol Lab Med 1986,
110(1):13–20. Erratum in: Arch Pathol Lab Med 1986, 110(10):958.
25. World Health Organization (WHO), New Delhi, India: WHO Weekly
epidemiological record - Global strategy for further reducing the leprosy burden
and sustaining leprosy control activities (plan period 2006–2010). New Delhi,
India: WHO; 2010.
26. Raffe SF, Thapa M, Khadge S, Tamang K, Hagge D, Lockwood DN: Diagnosis
and treatment of leprosy reactions in integrated services - the patients’
perspective in Nepal. PLoS Negl Trop Dis 2013, 7(3):e2089.
27. Douglas JT, Cellona RV, Fajardo TT, Abalos RM, Balagon MV, Klatser PR:
Prospective study of serological conversion as a risk factor for
development of leprosy among household contacts. Clin Diagn Lab
Immunol 2004, 11:897–900.
28. Bakker MI, Hatta M, Kwenang A, Van Mosseveld P, Faber WR, Klatser PR,
Oskam L: Risk factors for developing leprosy--a population-based cohort study
in Indonesia. Lepr Rev 2006, 77(1):48–61. Erratum in: Lepr Ver 2006, 77(2):170.
29. World Health Organization (WHO), Geneva, Switzerland: WHO Expert
Committee on Leprosy. Geneva, Switzerland: WHO; 1998.
30. Croft RP, Smith WC, Nicholls P, Richardus JH: Sensitivity and specificity of
methods of classification of leprosy without use of skin-smear
examination. Int J Lepr Other Mycobact Dis 1998, 66(4):445–450.
31. Martelli CM, Stefani MM, Gomes MK, Rebello PF, Peninni S, Narahashi K,
Maroclo AL, Costa MB, Silva SA, Sacchetim SC, Nery JA, Salles AM, Gillis TP,
Krahenbuhl JL, Andrade AL: Single lesion paucibacillary leprosy: baseline
profile of the Brazilian Multicenter Cohort Study. Int J Lepr Other Mycobact
Dis 2000, 68(3):247–257.
32. Roche PW, Failbus SS, Britton WJ, Cole R: Rapid method for diagnosis
of leprosy by measurements of antibodies to the M. leprae 35-kDa
protein: comparison with PGL-I antibodies detected by ELISA and
“dipstick” methods. Int J Lepr Other Mycobact Dis 1999, 67(3):279–286.
33. Young DB, Buchanan TM: A serological test for leprosy with a glycolipid
specific for Mycobacterium leprae. Science 1983, 221:1057–1059.
Cardoso et al. BMC Infectious Diseases 2013, 13:497 Page 9 of 10
http://www.biomedcentral.com/1471-2334/13/497
34. Roche PW, Britton WJ, Failbus SS, Neupane KD, Theuvenet WJ: Serological
monitoring of the response to chemotherapy in leprosy patients. Int J
Lepr Other Mycobact Dis 1993, 61(1):35–43.
35. Baumgart KW, Britton WJ, Mullins RJ, Basten A, Barnetson RS: Subclinical
infection with Mycobacterium leprae–a problem for leprosy control
strategies. Trans R Soc Trop Med Hyg 1993, 87(4):412–415.
36. Düppre NC, Camacho LA, Sales AM, Illarramendi X, Nery JA, Sampaio EP,
Sarno EN, Bührer-Sékula S: Impact of PGL-I seropositivity on the protective
effect of BCG vaccination among leprosy contacts: a cohort study.
PLoS Negl Trop Dis 2012, 6(6):e1711.
37. Frota CC, Freitas MV, Foss NT, Lima LN, Rodrigues LC, Barreto ML, Kerr LR:
Seropositivity to anti-phenolic glycolipid-I in leprosy cases, contacts and
no known contacts of leprosy in an endemic and a non-endemic area in
northeast Brazil. Trans R Soc Trop Med Hyg 2010, 104(7):490–495.
doi:10.1186/1471-2334-13-497
Cite this article as: Cardoso et al.: Development of a quantitative rapid
diagnostic test for multibacillary leprosy using smart phone technology.
BMC Infectious Diseases 2013 13:497.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Cardoso et al. BMC Infectious Diseases 2013, 13:497 Page 10 of 10
http://www.biomedcentral.com/1471-2334/13/497
